Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 30, 2017 08:05 ET | Source: Abeona Therapeutics Inc

Abeona Therapeutics Receives Rare Pediatric Disease Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa

NEW YORK and CLEVELAND, May 30, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for...
May 25, 2017 08:05 ET | Source: Abeona Therapeutics Inc

Abeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa

Abeona’s Third Gene Therapy Program to Receive FDA Orphan Designation EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) has Demonstrated Promising Efficacy and Safety in...
May 19, 2017 08:05 ET | Source: Abeona Therapeutics Inc

Abeona Therapeutics to Present at Multiple Upcoming Conferences

NEW YORK and CLEVELAND, May 19, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for...
May 16, 2017 08:05 ET | Source: Abeona Therapeutics Inc

Abeona Therapeutics Reports First Quarter 2017 Financial Results and Recent Business Highlights

NEW YORK and CLEVELAND, May 16, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for...
May 12, 2017 08:05 ET | Source: Abeona Therapeutics Inc

Abeona Therapeutics Announces Top-Line Data for ABO-102 Phase 1/2 MPS IIIA Gene Therapy Trial at ASGCT

--Positive dose response in central nervous system with 60.7% +/- 8.8% reduction of disease-causing heparan sulfate GAG observed in Cohort 2--Reduction of disease manifestation observed in decreased...
May 09, 2017 08:05 ET | Source: Abeona Therapeutics Inc

Abeona Therapeutics Receives Regulatory Approval to Initiate Clinical Trial in Australia with ABO-102 Gene Therapy For Patients with MPS IIIA

NEW YORK and CLEVELAND, May 09, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for...
May 08, 2017 08:05 ET | Source: Abeona Therapeutics Inc

Abeona Therapeutics Announces Gene Therapy Clinical Trial and Preclinical Program Presentations at ASGCT 20th Annual Meeting

NEW YORK and CLEVELAND, May 08, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for...
May 02, 2017 08:05 ET | Source: Abeona Therapeutics Inc

Abeona Therapeutics Provides Update on EB-101 Gene Therapy for Severe Form of Epidermolysis Bullosa from the Society for Investigative Dermatology Conference

--EB-101 Demonstrates Significant Wound Healing (defined as greater than 50% healed) in 100% of Treated Wounds (36/36) at 3 Months; 89% (32/36) at 6 months, 83% (20/24) at 12 months, 88% (21/24) at 24...
April 25, 2017 08:05 ET | Source: Abeona Therapeutics Inc

Abeona Therapeutics Announces EB-101 Clinical Update to be Presented at the Society for Investigative Dermatology Annual Meeting

NEW YORK and CLEVELAND, April 25, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies...
April 20, 2017 08:05 ET | Source: Abeona Therapeutics Inc

Abeona to Present At Multiple Upcoming Conferences

NEW YORK and CLEVELAND, April 20, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for...